蛋白别名（Synonyms）

HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100

种属（Species)

Human

表达系统（Source）

HEK293

表达序列（Sequence）

Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YLEPGPVTA peptide

Accession

A0A140T913(HLA-A*02:01)&P61769(B2M)&YLEPGPVTA

标签（Tag)

C-His-Avi

分子量（Molecular Weight）

The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.

内毒素（Endotoxin）

Less than 1EU per μg by the LAL method.

纯度（Purity）

> 95% as determined by Bis-Tris PAGE;
> 95% as determined by HPLC

活性（Activity）

ELISA Data: Immobilized Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Antibody, hFc Tag with the EC50 of 5.6ng/ml determined by ELISA .

SPR Data: Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer, His Tag immobilized on CM5 Chip can bind Tebentafusp with an affinity constant of 0.196 nM as determined in SPR assay .

制剂（Formulation）

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

外观（Appearance）

冻干粉